Business Context and Reporting Period
This Form 8-K Current Report was filed by Actinium Pharmaceuticals, Inc. (ATNM) on June 28, 2022. The filing discloses the entry into a material definitive agreement regarding the company's equity financing arrangements.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the terms of a sales agreement.
Material Changes
On June 28, 2022, the Company entered into an Amended and Restated Capital on Demand Sales Agreement (the "A&R Sales Agreement") with JonesTrading Institutional Services LLC and B. Riley Securities, Inc. This agreement modifies the Original Sales Agreement dated August 7, 2020, by adding B. Riley Securities as an additional sales agent. The agreement allows for the sale of common stock in "at the market offerings" up to an aggregate offering amount of $200,000,000.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the representations, warranties, and covenants in the A&R Sales Agreement are for the benefit of the parties to the agreement and should not be relied upon as statements of fact regarding the Company's actual condition. The document explicitly states it does not constitute an offer to sell or a solicitation of an offer to buy securities.
Investor Verification Checklist
- Verify the total amount of shares sold under the Original Sales Agreement and the A&R Sales Agreement to date.
- Review the specific compensation terms and fees payable to JonesTrading and B. Riley Securities under the new agreement.
- Check subsequent filings for any actual sales of shares executed under this agreement.
- Confirm the current cash position of the company to assess the necessity of this financing mechanism.